NCT06232655
Cladribine Venetoclax in Monocytic AML
Study of Cladribine+Venetoclax After Failure of Venetoclax+Hypomethylating Agent in Monocytic AML
University of Colorado, Denver·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Acute Myeloid Leukemia
- Drug/Device/Intervention
- Cladribine
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- University of Colorado, Denver
- Location
- Aurora, United States of America
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Dec 01, 2024
- End date
- Oct 01, 2027
- Enrollment
- 40 participants
Primary outcome
Overall response rate (ORR)
Summary
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of
 hypomethylating agent+venetoclax
ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06232655
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06232655 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Colorado, Denver and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.